Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
argenx SE

argenx SE (ARGX) Stock Overview

Explore argenx SE’s financial performance, market position, analyst ratings, and future outlook.

ARGX●NASDAQ
HealthcareBiotechnology
$972.25
$12.76(1.33%)
U.S. Market opens in 3h 7m

argenx SE (ARGX)

Meyka AI Score

Z

Key Financials

Market Cap60.5B
P/E Ratio35.10
EPS (TTM)$27.73
ROE0.24%
Fundamental Analysis

AI Price Forecasts

1 Month$1059.57
3 Months$1111.62
1 Year Target$894.36

ARGX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of argenx SE (NASDAQ: ARGX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, argenx SE's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ARGX on the NASDAQ shows an RSI of 48.35, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $894.36 for the NASDAQ listing.

Key metrics behind argenx SE's NASDAQ-traded stock include a P/E ratio of 35.10 and a market capitalization of 60.5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ARGX on the NASDAQ.

Price Performance (NASDAQ: ARGX)

1-Day Change
1.33%
5-Day Change
-0.24%
1-Month Change
-4.98%
3-Month Change
9.59%
6-Month Change
40.62%
Year-to-Date (YTD) Change
15.61%
1-Year Change
35.22%
3-Year Change
100.07%
5-Year Change
227.75%
All-Time (Max) Change
4127.17%

Contact Information

https://www.argenx.com
31 10 703 8441
Laarderhoogtweg 25, Amsterdam, NH, 1101 EB

Company Facts

18,630 Employees
IPO DateMay 18, 2017
CountryNL
Actively Trading

Frequently Asked Questions